Aclaris Therapeutics, Inc.
US ˙ NasdaqGS ˙ US00461U1051

SecurityACRS / Aclaris Therapeutics, Inc.
InstitutionDimensional Fund Advisors Lp
Latest Disclosed Ownership511,461 shares
Latest Disclosed Value $ 1,914,370
Dimensional Fund Advisors Lp reports 88.84% increase in ownership of ACRS / Aclaris Therapeutics, Inc.

On May 7, 2026 - Dimensional Fund Advisors Lp filed a 13F-HR form disclosing ownership of 511,461 shares of Aclaris Therapeutics, Inc. (US:ACRS) valued at $1,917,979 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 270,850 shares of Aclaris Therapeutics, Inc.. This represents a change in shares of 88.84% during the quarter. The current value of the position is $2,229,970 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F ACLARIS THERAPEUTICS COM 00461U105 511,461 240,611 88.84 1,914 135.14 0.0004
2026-02-12 2025-12-31 13F ACLARIS THERAPEUTICS COM 00461U105 270,850 106,606 64.91 815 160.90 0.0002
2025-11-12 2025-09-30 13F ACLARIS THERAPEUTICS COM 00461U105 164,244 -43,029 -20.76 312 6.12 0.0001
2025-08-12 2025-06-30 13F ACLARIS THERAPEUTICS COM 00461U105 207,273 -147,576 -41.59 295 -45.86 0.0001
2025-05-13 2025-03-31 13F ACLARIS THERAPEUTICS COM 00461U105 354,849 115,254 48.10 543 -8.59 0.0001
2025-02-13 2024-12-31 13F ACLARIS THERAPEUTICS COM 00461U105 239,595 162,785 211.93 594 575.00 0.0001
2024-11-07 2024-09-30 13F ACLARIS THERAPEUTICS COM 00461U105 76,810 51 0.07 88 4.76 0.0000
2024-08-09 2024-06-30 13F ACLARIS THERAPEUTICS COM 00461U105 76,759 -12,302 -13.81 84 -23.64 0.0000
2024-05-10 2024-03-31 13F ACLARIS THERAPEUTICS COM 00461U105 89,061 -98,492 -52.51 110 -43.88 0.0000
2024-02-07 2023-12-31 13F ACLARIS THERAPEUTICS COM 00461U105 187,553 -74,180 -28.34 197 -89.06 0.0001
2023-11-09 2023-09-30 13F ACLARIS THERAPEUTICS COM 00461U105 261,733 161,276 160.54 1,793 72.14 0.0006
2023-08-09 2023-06-30 13F ACLARIS THERAPEUTICS COM 00461U105 100,457 -37,466 -27.16 1,042 -6.64 0.0003
2023-05-12 2023-03-31 13F ACLARIS THERAPEUTICS COM 00461U105 137,923 89,906 187.24 1,116 0.0004
2023-02-09 2022-12-31 13F ACLARIS THERAPEUTICS COM 00461U105 48,017 0 0.00 1 -100.00 0.0002
2022-11-10 2022-09-30 13F ACLARIS THERAPEUTICS COM 00461U105 48,017 48,017 756 0.0003
2022-02-09 2021-12-31 13F ACLARIS THERAPEUTICS COM 00461U105 0 -18,640 -100.00 0 -100.00
2021-11-12 2021-09-30 13F ACLARIS THERAPEUTICS COM 00461U105 18,640 0 0.00 336 2.75 0.0001
2021-08-12 2021-06-30 13F ACLARIS THERAPEUTICS COM 00461U105 18,640 0 0.00 327 -30.43 0.0001
2021-05-14 2021-03-31 13F ACLARIS THERAPEUTICS COM 00461U105 18,640 0 0.00 470 288.43 0.0002
2021-03-08 2020-12-31 13F/A-2 ACLARIS THERAPEUTICS COM 00461U105 18,640 8 0.04 121 152.08 0.0000
2021-02-11 2020-12-31 13F ACLARIS THERAPEUTICS COM 00461U105 18,640 8 121 43.6988
2020-11-12 2020-09-30 13F ACLARIS THERAPEUTICS COM 00461U105 18,632 7,219 63.25 48 166.67 0.0000
2020-08-13 2020-06-30 13F ACLARIS THERAPEUTICS COM 00461U105 11,413 0 0.00 18 50.00 0.0000
2020-05-14 2020-03-31 13F ACLARIS THERAPEUTICS COM 00461U105 11,413 0 0.00 12 -45.45 0.0000
2020-02-14 2019-12-31 13F ACLARIS THERAPEUTICS COM 00461U105 11,413 -533,312 -97.90 22 -96.26 0.0000
2019-11-12 2019-09-30 13F ACLARIS THERAPEUTICS COM 00461U105 544,725 -356,318 -39.55 588 -70.20 0.0002
2019-08-13 2019-06-30 13F ACLARIS THERAPEUTICS COM 00461U105 901,043 151,916 20.28 1,973 -56.03 0.0008
2019-08-12 2019-03-31 13F/A-2 ACLARIS THERAPEUTICS COM 00461U105 749,127 259,611 53.03 4,487 24.02 0.0018
2019-05-10 2019-03-31 13F ACLARIS THERAPEUTICS COM 00461U105 749,127 259,611 4,487
2019-02-26 2018-12-31 13F/A-1 ACLARIS THERAPEUTICS COM 00461U105 489,516 250,963 105.20 3,618 4.45 0.0016
2019-02-13 2018-12-31 13F ACLARIS THERAPEUTICS COM 00461U105 489,516 250,963 3,618
2018-11-13 2018-09-30 13F ACLARIS THERAPEUTICS COM 00461U105 238,553 222,836 1,417.80 3,464 1,003.18 0.0013
2018-08-10 2018-06-30 13F ACLARIS THERAPEUTICS COM 00461U105 15,717 0 0.00 314 14.18 0.0001
2018-05-11 2018-03-31 13F ACLARIS THERAPEUTICS COM 00461U105 15,717 0 0.00 275 -29.12 0.0001
2018-02-12 2017-12-31 13F ACLARIS THERAPEUTICS COM 00461U105 15,717 15,717 388 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.